InflaRx NV (IFRX) Analyzed By Guggenheim with $65 Target; Whitehorse Finance (WHF)’s Sentiment Is 1.78

Professional analysts at Guggenheim has “Buy” rating on InflaRx NV (IFRX). The firm has begun coverage in an analyst note revealed to clients on Friday, 22 February. Guggenheim’s TP suggests upside of 102.81% from the company’s last price.

Whitehorse Finance Inc (WHF) investors sentiment increased to 1.78 in 2018 Q3. It’s up 0.28, from 1.5 in 2018Q2. The ratio has increased, as 16 hedge funds started new or increased equity positions, while 9 cut down and sold their positions in Whitehorse Finance Inc. The hedge funds in our database now possess: 1.93 million shares, up from 1.01 million shares in 2018Q2. Also, the number of hedge funds holding Whitehorse Finance Inc in top ten equity positions was flat from 0 to 0 for the same number . Sold All: 5 Reduced: 4 Increased: 7 New Position: 9.

The stock increased 4.24% or $0.59 during the last trading session, reaching $14.5. About 301,837 shares traded or 625.13% up from the average. WhiteHorse Finance, Inc. (WHF) has declined 1.95% since February 24, 2018 and is downtrending. It has underperformed by 1.95% the S&P500. Some Historical WHF News: 23/05/2018 – WHITE HORSE BHD WHSE.KL – YEAR-AGO QTRLY NET PROFIT 4.2 MLN RGT; YEAR-AGO QTRLY REV 142.6 MLN RGT; 09/05/2018 – WHITEHORSE FINANCE INC WHF.O : DEUTSCHE BANK RAISES TARGET PRICE TO $15 FROM $14.50; 29/03/2018 – WHITEHORSE FINANCE INC WHF.O : DEUTSCHE BANK STARTS WITH BUY; TARGET PRICE $14.50; 12/03/2018 WhiteHorse Finance, Inc. Announces Quarterly Distribution; 08/05/2018 – WHITEHORSE FINANCE INC – QTRLY SHR $0.68; 08/05/2018 – WhiteHorse Finance 1Q EPS 68c; 16/04/2018 – S&PGR Raises Four, Affirms Two WhiteHorse VI Ltd. Rtgs

Ares Management Llc holds 0.67% of its portfolio in WhiteHorse Finance, Inc. for 972,622 shares. Ativo Capital Management Llc owns 78,023 shares or 0.29% of their US portfolio. Moreover, Advisors Asset Management Inc. has 0.09% invested in the company for 396,990 shares. The Virginia-based Fj Capital Management Llc has invested 0.03% in the stock. Eqis Capital Management Inc., a California-based fund reported 13,449 shares.

Analysts await WhiteHorse Finance, Inc. (NASDAQ:WHF) to report earnings on March, 1. They expect $0.37 EPS, up 12.12% or $0.04 from last year’s $0.33 per share. WHF’s profit will be $7.60M for 9.80 P/E if the $0.37 EPS becomes a reality. After $0.35 actual EPS reported by WhiteHorse Finance, Inc. for the previous quarter, Wall Street now forecasts 5.71% EPS growth.

WhiteHorse Finance, LLC is a busine

Since January 1, 0001, it had 3 insider buys, and 2 selling transactions for $26.89 million activity.

More notable recent WhiteHorse Finance, Inc. (NASDAQ:WHF) news were published by: Nasdaq.com which released: “Roche, joining rivals, donates haemophilia drug to boost access – Nasdaq” on February 06, 2019, also Seekingalpha.com with their article: “WhiteHorse JV to invest in lower midmarket debt – Seeking Alpha” published on January 18, 2019, Seekingalpha.com published: “WhiteHorse Finance: This 6.50% Baby Bond Has Begun Trading On The Nasdaq – Seeking Alpha” on December 03, 2018. More interesting news about WhiteHorse Finance, Inc. (NASDAQ:WHF) were released by: Seekingalpha.com and their article: “WhiteHorse Finance sees Bayside Funds gradually reducing stake – Seeking Alpha” published on September 04, 2018 as well as Nasdaq.com‘s news article titled: “WhiteHorse Finance, Inc. (WHF) Ex-Dividend Date Scheduled for December 17, 2018 – Nasdaq” with publication date: December 14, 2018.

Analysts await InflaRx N.V. (NASDAQ:IFRX) to report earnings on April, 4. After $-0.31 actual EPS reported by InflaRx N.V. for the previous quarter, Wall Street now forecasts 32.26% negative EPS growth.

Among 2 analysts covering InflaRx (IFRX), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. InflaRx has $62 highest and $47 lowest target. $54.50’s average target is 70.05% above currents $32.05 stock price. InflaRx had 2 analyst reports since December 10, 2018 according to SRatingsIntel.

More notable recent InflaRx N.V. (NASDAQ:IFRX) news were published by: Nasdaq.com which released: “Richard Brudnick to Join InflaRx Board of Directors – Nasdaq” on February 14, 2019, also Globenewswire.com with their article: “InflaRx Announces Presentation of New Clinical Data with Lead Candidate IFX-1 in Hidradenitis Suppurativa – GlobeNewswire” published on February 06, 2019, Nasdaq.com published: “EURO Ressources reports earnings for the year ended December 31, 2018 – Nasdaq” on February 22, 2019. More interesting news about InflaRx N.V. (NASDAQ:IFRX) were released by: Nasdaq.com and their article: “Notice Regarding Voluntary Adoption of International Financial Reporting Standards (IFRS) – Nasdaq” published on February 07, 2019 as well as Nasdaq.com‘s news article titled: “Kirkland Lake Gold Reports Record Earnings and Cash Flow in Q4 and Full-Year 2018 – Nasdaq” with publication date: February 21, 2019.

InflaRx N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology in the United States. The company has market cap of $822.47 million. The Company’s C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. It currently has negative earnings. The firm is involved in developing IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and other chronic/autoimmune diseases, as well as IFX-2 for the treatment of chronic inflammation and autoimmune diseases.

WhiteHorse Finance, Inc. (NASDAQ:WHF) Institutional Positions Chart

http://endigest.com/
http://endigest.com/http://endigest.com/

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.



Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *